![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Stoevelaar H.J. McDonnell J.
Publisher: Adis International
ISSN: 1170-7690
Source: PharmacoEconomics, Vol.19, Iss.2, 2001-01, pp. : 131-153
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Treatment options for benign prostatic hyperplasia
By Thurlow R.J.
Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dutasteride for the treatment of benign prostatic hyperplasia
Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dutasteride/Tamsulosin: In Benign Prostatic Hyperplasia
Drugs & Aging, Vol. 29, Iss. 5, 2012-05 ,pp. :